Angiogenesis News and Research RSS Feed - Angiogenesis News and Research

Angiogenesis is blood vessel formation. Tumor angiogenesis is the growth of new blood vessels that tumors need to grow. This is caused by the release of chemicals by the tumor.
FDA approves EYLEA Injection for treatment of Diabetic Macular Edema

FDA approves EYLEA Injection for treatment of Diabetic Macular Edema

Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has approved EYLEA (aflibercept) Injection for the treatment of Diabetic Macular Edema (DME). [More]
UTHealth scientists identify inhibitory switch to prevent peripheral vascular disease

UTHealth scientists identify inhibitory switch to prevent peripheral vascular disease

Millions of people in the United States have a circulatory problem of the legs called peripheral vascular disease. It can be painful and may even require surgery in serious cases. This disease can lead to severe skeletal muscle wasting and, in turn, limb amputation. [More]
Phase 3 trial: NEXAVAR tablets fail to meet primary endpoint in HER2-negative breast cancer patients

Phase 3 trial: NEXAVAR tablets fail to meet primary endpoint in HER2-negative breast cancer patients

Bayer HealthCare and Onyx Pharmaceuticals Inc., an Amgen subsidiary, today announced that an investigational Phase 3 trial of NEXAVAR (sorafenib) tablets in patients with advanced breast cancer did not meet its primary endpoint of improving progression-free survival (PFS). [More]
Kinex receives FDA approval to begin Phase I study of KX2-391 Ointment for actinic keratosis

Kinex receives FDA approval to begin Phase I study of KX2-391 Ointment for actinic keratosis

Kinex Pharmaceuticals announced the receipt of an allowance by the US FDA for the Company's KX2-391 Ointment for the commencement of a Phase I clinical study in actinic keratosis. This is the Company's third IND to be allowed by the US FDA in the past 12 months. [More]
AMSBIO-Trevigen prize winner announced

AMSBIO-Trevigen prize winner announced

AMSBIO, regular sponsor of the annual Beatson International Cancer Conference announces that the winner of the AMSBIO-Trevigen prize for the best poster was Katarzyna Grzes - a PhD researcher specialising in Cell Signaling and Immunology at the University of Dundee (Scotland, UK).
Miss Grzes was named as winner of the Poster Prize for the best presented and most interesting poster for her work entitled 'Metabolic regulation in PTEN null T lymphoma / leukemia'. [More]
Targeting CXCR4–CXCL12–CXCR7 axis combats mTOR inhibitor resistance in renal cancer

Targeting CXCR4–CXCL12–CXCR7 axis combats mTOR inhibitor resistance in renal cancer

There is considerable crosstalk between the CXCR4–CXCL12–CXCR7 axis and the mammalian target of rapamycin pathway in human renal cell carcinoma, and targeting the axis may overcome drug resistance to mTOR inhibitors, researchers suggest. [More]
Marker identified for population of renal cancer cells with stem-cell-like features

Marker identified for population of renal cancer cells with stem-cell-like features

Researchers have identified a population of clear cell renal cell carcinoma cells positive for the CTR2 marker that possess some stem-cell-like features and are able to induce an angiogenic response in vivo. [More]
Marker identified for population of renal cancer cells with stem-cell-like features

Marker identified for population of renal cancer cells with stem-cell-like features

Researchers have identified a population of clear cell renal cell carcinoma cells positive for the CTR2 marker that possess some stem-cell-like features and are able to induce an angiogenic response in vivo. Targeting CTR2 was shown to decrease drug resistance to cisplatin. [More]
Researchers create combination drug that controls both tumor growth and metastasis

Researchers create combination drug that controls both tumor growth and metastasis

Researchers at UC Davis, University of Massachusetts and Harvard Medical School have created a combination drug that controls both tumor growth and metastasis. By combining a COX-2 inhibitor, similar to Celebrex, and an epoxide hydrolase (sEH) inhibitor, the drug controls angiogenesis (blood vessel formation), limiting a tumor's ability to grow and spread. [More]
Research into cell metabolism could open new therapeutic avenues for diabetes, cancer

Research into cell metabolism could open new therapeutic avenues for diabetes, cancer

More scientific research into the metabolism of stromal support cells and immune cells - and the role of the metabolism of these cell types in the development of diseases - could open new therapeutic avenues for diabetes, inflammatory conditions and cancer. That was the conclusion of a review article by scientists from VIB and KU Leuven in the leading journal Nature. [More]
Bayer announces Health Canada approval of Nexavar for differentiated thyroid cancer treatment

Bayer announces Health Canada approval of Nexavar for differentiated thyroid cancer treatment

Bayer Inc. is pleased to announce the Health Canada approval of Nexavar for the treatment of patients with locally advanced or metastatic, progressive, differentiated thyroid carcinoma (DTC), refractory to radioactive iodine (RAI). [More]
Researchers discover mechanical threshold that regulates angiogenesis

Researchers discover mechanical threshold that regulates angiogenesis

Angiogenesis, the sprouting of new blood vessels from pre-existing ones, is essential to the body's development. As organs grow, vascular networks must grow with them to feed new cells and remove their waste. [More]
Mayo Clinic researchers uncover 31 genes key to clear cell renal cell carcinoma

Mayo Clinic researchers uncover 31 genes key to clear cell renal cell carcinoma

A genomic analysis of clear cell renal cell carcinoma (ccRCC), the most common form of kidney cancer, from 72 patients has uncovered 31 genes that are key to development, growth and spread of the cancer, say researchers from Mayo Clinic in Florida. [More]
Metabolic pathway genes linked to AMD and choroidal vasculopathy

Metabolic pathway genes linked to AMD and choroidal vasculopathy

The cholesteryl ester transfer protein gene appears to increase susceptibility to neovascular age-related macular degeneration and polypoidal choroidal vasculopathy, research shows. [More]
Cardium reports positive results from Generx Ad5FGF-4 Phase 3 study for treatment of myocardial ischemia

Cardium reports positive results from Generx Ad5FGF-4 Phase 3 study for treatment of myocardial ischemia

Taxus Cardium Pharmaceuticals Group Inc. will report today at the Biotechnology Industry Organization’s 2014 BIO International Convention on a pre-specified interim analysis from its international ASPIRE Phase 3 registration clinical study of Generx Ad5FGF-4, Cardium Therapeutics’ angiogenic gene therapy product candidate for patients with myocardial ischemia due to coronary artery disease. [More]

Overview of cancer cytokines therapy market

Cytokines, a major group in the protein therapeutics umbrella, are known to be soluble extracellular proteins or glycoproteins which are crucial intercellular regulators, having the capacity to mobilize the cells which are engaged in innate as well as adaptive inflammatory host defenses, cell growth, differentiation, cell death, angiogenesis, and development and repair processes aimed at the restoration of homeostasis. [More]
NIH receives $10 million grant for research on breast cancer metastasis

NIH receives $10 million grant for research on breast cancer metastasis

The American Cancer Society predicts that 40,000 American women will die from breast cancer this year. Most of those deaths will occur due to cells from the primary tumor that spread to other parts of the body-the process known as metastasis. [More]
New treatment for ovarian cancer can improve response rates

New treatment for ovarian cancer can improve response rates

Doctors at the University of Arizona Cancer Center at St. Joseph's Hospital and Medical Center in Phoenix reported today in Lancet Oncology that a new treatment for ovarian cancer can improve response rates (increase the rate of tumor shrinkage) and prolong the time until cancers recur. [More]
Researchers discover crucial process that regulates development of blood vessels

Researchers discover crucial process that regulates development of blood vessels

Biologists at The Scripps Research Institute (TSRI) have discovered a crucial process that regulates the development of blood vessels. [More]
Compound developed as cholesterol-fighting molecule can kill cancerous cells

Compound developed as cholesterol-fighting molecule can kill cancerous cells

Researchers at the University of Missouri have proven that a compound initially developed as a cholesterol-fighting molecule not only halts the progression of breast cancer, but also can kill the cancerous cells. [More]